Is it safe to take Mounjaro for years?

The longest randomized data cover 176 weeks, about 3 years and 4 months, and the safety profile matched the earlier 72-week results. Gastrointestinal effects were the main problem and clustered in the first 20 weeks. Beyond 3 years there is no controlled evidence yet, so ongoing use relies on regular monitoring rather than a proven ceiling.

Do I need thyroid blood tests while on Mounjaro?

The label says routine calcitonin testing or thyroid ultrasound is of uncertain value and may lead to unnecessary procedures. Instead, report a neck lump, trouble swallowing, shortness of breath, or persistent hoarseness to your clinician. People with a personal or family history of medullary thyroid carcinoma or MEN 2 should not take the drug at all.

Can I drop to a lower dose instead of stopping completely?

The Zepbound label allows a lower maintenance dose when a higher one is not tolerated, and 5 mg, 10 mg, and 15 mg are all approved maintenance doses. There is no trial that tested a planned taper to zero. Any dose change should be made with your prescriber and followed with weight and lab checks.

How fast does weight return after stopping tirzepatide?

In SURMOUNT-4, people who switched to placebo after 36 weeks regained 14.0% of body weight over the next 52 weeks, against a further 5.5% loss in those who continued. About 82% regained more than a quarter of what they had lost within a year. Blood pressure and waist size rose along with the weight.

Does long-term Mounjaro use raise the risk of gallstones?

Gallbladder events were slightly more common in the Zepbound weight trials: cholelithiasis 1.1% versus 1% on placebo, and cholecystitis 0.7% versus 0.2%. The label links these events to weight loss itself rather than to the drug alone. Sudden pain in the upper right abdomen, especially after meals, should be checked.

How Long Can You Safely Stay on Mounjaro?

The short answer: There is no fixed stop date. The FDA labels for Mounjaro and Zepbound treat tirzepatide as long-term therapy for chronic conditions, and neither sets a maximum duration. Controlled trial data now run to 176 weeks (about 3 years and 4 months), with a safety profile that matched the earlier 72-week results. Beyond that point the evidence thins out, so long-term use is a decision to revisit with your clinician at each check-in.

Does the FDA label set a time limit?

No. The Mounjaro prescribing information (revised December 2025) approves tirzepatide "as an adjunct to diet and exercise to improve glycemic control" in adults and children aged 10 and older with type 2 diabetes. Diabetes does not go away, and the label describes maintenance dosing of 5 mg to 15 mg once weekly with no end point.

The Zepbound label (revised January 2026) is even more direct. Its indication is "to reduce excess body weight and maintain weight reduction long term." The phrase "long term" is in the approved indication itself. The label adds that the 2.5 mg starting dose "is not approved as a maintenance dosage," and it names 5 mg, 10 mg, or 15 mg as the maintenance doses. The regulator expects people to reach a working dose and stay there. Our Mounjaro dosing schedule guide covers the titration.

Professional societies agree. In March 2026 The Obesity Society, the Obesity Medicine Association, and the Obesity Action Coalition issued joint guidance that called obesity "a chronic, often progressive, disease" and said obesity medications "are not a temporary solution." The published guidance gives a strong recommendation for continuing obesity medications during weight maintenance. The OMA's 2026 Obesity Algorithm frames care around "an individualized, long-term treatment plan."

How long have people taken tirzepatide in trials?

The diabetes trials came first. The Mounjaro label lists SURPASS-1, -2, and -5 at 40 weeks, SURPASS-3 at 52 weeks, and SURPASS-4 at 104 weeks (2 years). SURPASS-4 randomized 2,002 adults with type 2 diabetes and high cardiovascular risk. In the Lancet report, tirzepatide showed no excess cardiovascular risk against insulin glargine (hazard ratio 0.74, 95% CI 0.51 to 1.08).

The obesity trials ran longer. The Zepbound label pools 2,519 adults treated for up to 72 weeks in SURMOUNT-1 and SURMOUNT-2. The SURMOUNT-1 extension went further. A subgroup of 1,032 adults with prediabetes stayed on tirzepatide or placebo for 176 weeks, then had a 17-week off-treatment period, for 193 weeks in total. Results appeared in the New England Journal of Medicine. At 176 weeks, mean weight change was -12.3% on 5 mg, -18.7% on 10 mg, and -19.7% on 15 mg, versus -1.3% on placebo. Progression to type 2 diabetes was 1.3% with tirzepatide and 13.3% with placebo (hazard ratio 0.07). Gastrointestinal side effects were the main adverse events, and most occurred in the first 20 weeks.

That 176-week dataset is the longest randomized evidence for tirzepatide. Three years of continuous use is well studied. Five or ten years is not.

What happens if you stop?

The weight tends to come back. SURMOUNT-4, published in JAMA, was built to test this. All 783 participants took tirzepatide for a 36-week lead-in and lost a mean of 20.9% of body weight. Then 670 were randomized to keep taking tirzepatide or switch to placebo for 52 more weeks. From week 36 to week 88, the tirzepatide group lost a further 5.5%. The placebo group regained 14.0%. The difference was 19.4 percentage points. At week 88, 89.5% of people still on tirzepatide had kept at least 80% of their weight loss. Only 16.6% of the placebo group had.

The health gains reversed too. A post hoc analysis in JAMA Internal Medicine followed the 308 placebo-arm participants. About 82% regained more than 25% of the lost weight within one year. Those who regained 75% or more saw waist circumference rise by 14.7 cm and systolic blood pressure rise by 10.4 mm Hg. Those who regained less than 25% held their waist steady (a 0.8 cm change).

The SURMOUNT-1 extension showed a smaller version of the same effect. After 17 weeks off treatment, type 2 diabetes had been diagnosed in 2.4% of former tirzepatide users, up from 1.3% at the end of treatment. See Mounjaro weight regain after stopping for the full pattern.

What should be monitored during long-term use?

The labels list the risks that matter over years, not weeks.

Thyroid C-cell tumors (boxed warning). In a 2-year rat study, tirzepatide caused a dose-dependent and duration-dependent rise in thyroid C-cell tumors. The label states it "is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans." The drug is contraindicated with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2. Routine calcitonin blood tests or thyroid ultrasound are "of uncertain value," so the label does not call for them. Report a neck mass, trouble swallowing, shortness of breath, or persistent hoarseness.
Acute pancreatitis. Across the diabetes trials, 14 adjudicated events occurred in 13 tirzepatide-treated patients (0.23 per 100 patient-years) versus 3 events in comparator patients (0.11 per 100 patient-years). In the pooled Zepbound weight trials, 0.2% of treated patients had confirmed pancreatitis. Persistent, severe abdominal pain that may spread to the back is the warning sign. A 2025 UK hospital audit found 4 tirzepatide users among 222 pancreatitis admissions, all mild.
Gallbladder disease. In the Zepbound trials, cholelithiasis occurred in 1.1% of treated patients versus 1% on placebo, cholecystitis in 0.7% versus 0.2%, and cholecystectomy in 0.2% versus none. The label ties these events to weight loss itself.
Diabetic retinopathy. Rapid improvement in glucose control can temporarily worsen retinopathy. People with type 2 diabetes and a history of retinopathy should have it monitored for progression.
Kidney function. Postmarketing reports include acute kidney injury, mostly after dehydration from nausea, vomiting, or diarrhea. The label advises checking renal function when those symptoms appear.

Day-to-day side effects usually ease after titration. See Mounjaro side effects management.

Where does the evidence run out?

Three places. First, duration. The longest placebo-controlled data stop at 176 weeks, from one prediabetes subgroup of one trial. There is no randomized tirzepatide data at 5 or 10 years. Second, population. SURMOUNT-1, -3, and -4 excluded people with type 2 diabetes. Real-world patients with more conditions are less studied. Third, the thyroid question. The rodent signal is real, but the human relevance "has not been determined."

Dropout also shapes long-term results. In the pooled 72-week Zepbound trials, 4.8%, 6.3%, and 6.7% of patients on 5 mg, 10 mg, and 15 mg stopped for adverse reactions, versus 3.4% on placebo. In SURMOUNT-4, 14.4% left before randomization at week 36. The people who stay for 3 years are, by definition, people who tolerate the drug.

Who might taper or stop?

The labels do not describe a taper protocol. They do name situations that call for stopping: suspected pancreatitis, a serious hypersensitivity reaction, pregnancy, and, for Zepbound, suicidal thoughts or behavior.

Outside those cases, the decision is individual. Some people reach a target and want a lower maintenance dose. The Zepbound label allows this: "If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage." Others face cost or supply problems. Whatever the reason, SURMOUNT-4 shows that an outright stop returns much of the lost weight within a year. A planned, monitored change with your prescriber is safer than an abrupt stop. The same questions apply across the drug class, and glp1.md covers semaglutide and other GLP-1 medicines.

The bottom line

You can stay on Mounjaro as long as it keeps working, you tolerate it, and your clinician keeps checking the risks on the label. The FDA treats tirzepatide as long-term therapy for two chronic diseases, and the major obesity societies recommend continuing medication through weight maintenance. Randomized evidence supports about 3 years of continuous use with a stable safety profile. In SURMOUNT-4, stopping erased about half of the weight loss within a year (net loss fell from 20.9% to 9.9%). Beyond 3 years, the data are still being collected. Keep the check-ins, know the warning signs for pancreatitis, gallbladder disease, and thyroid symptoms, and make any change on purpose rather than by default.

Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Decisions about starting, continuing, changing, or stopping tirzepatide should be made with a licensed prescriber who knows your health history.